Table 3.
Antimicrobial therapies used in mixed second- and third-line therapy studies.
| Study | Previous treatments | Drug resistances before SGT | Empiric therapy | N | Treatment duration | SGT | N | Treatment duration |
|---|---|---|---|---|---|---|---|---|
| Fiorini et al. [2013] | Not reported | L + C + M 33% (79/236) L + C 3% (8/236) L + M 3% (7/236) C + M 25% (60/236) C 20% (48/236) M 4% (10/10) |
Not administered | – | – | Susceptible to L: ES 40 mg, A 1g, L 250 mg b.d. |
131 | 10 days |
| Resistant to L: ES 40 mg, A 1 g b.d., RFB 150 mg o.d. |
105 | 12 days | ||||||
| Tay et al. [2012] | First line: O, A, C 7-day Second line: O, A, C/M 7-14 days |
C 94% (288/306) M 68% (207/306) C and M 65% (199/306) CIP 5.6% RIF 2% A 0% TE 0% |
Not administered | – | – | Susceptible to RFB and CIP, no penicillin allergy: RA 20 mg t.d.s., A 1 g t.d.s., RFB 150 mg b.d., CIP 500 mg b.d. |
210 | RA and A 10 days. RFB and CIP 5 days |
| Susceptible to RIF and CIP, penicillin allergy: RA 20 mg t.d.s., B 240 q.d, RFB 150 mg b.d., CIP 500 mg b.d. |
69 | 10 days | ||||||
| Resistant to RIF or CIP or failure of RIF and CIP-based therapy: PPI, B, FU, A or RFB PPI, A, M PPI, B, TE, FU or A |
26 | 10 days | ||||||
| Yahav et al. [2006] | First: O, C, A or O, M, A 7-day Second: O,C, M, A or O, B, M, TE 7-day |
M 47% (23/49) C 59% (29/49) Both C and M 29% (14/49) |
O 20 mg, A 1 g, C 500 mg b.d. | 11 | 7 days | Susceptible to C: O 20 mg, A 1 g, C 500 mg b.d. |
34 | 7 days |
| O 20 mg, A 1 g, M 500 mg b.d. | 6 | 7 days | Resistant to C and susceptible to M: O 20 mg, A 1 g, M 500 mg b.d. |
|||||
| O 20 mg b.d., B 120 q.d., M 500 mg b.d., TE 500 mg q.d. | 11 | 7 days | Allergic to penicillin: O 20 mg b.d., B 120 q.d.s., TE 500 mg q.d., M 500 mg b.d. |
15 | 7 days | |||
| Resistant to C and M: O 20 mg b.d., B 120 mg q.d., TE 500 mg q.d., A 1 g b.d. |
A, amoxicillin; b.d., twice a day; B, bismuth; C, clarithromycin; CIP, ciprofloxacin; FU, furazolidone; L, levofloxacin; M, metronidazole; O, omeprazole; o.d., once a day; RA, rabeprazole; RFB, rifabutin; RIF, rifampicin; t.d.s., three times a day; TE, tetracycline; SGT, susceptibility-guided therapy.